Curtis Nickel, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    HengRui
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Valensa
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    Inmunotek
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    MicroGenDx
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    TEVA
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (General Urology)
    Ineligible company:
    RedLeaf Medical
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Alivio Therapeutics
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Seikagaku Corporation
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Farr Laboratories
    Date added:
    Date updated:
    05/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (General Urology)
    Ineligible company:
    UTIVA
    Date added:
    Date updated:
    05/13/2024

Pages

Return to Update Series (2022) Lesson 21: The Changing Role of Fluoroquinolones for Prophylaxis and Treatment of Urological Infections